PCSK9 Inhibitor Trends in Type 1 Diabetes
PCSK9 had a significant correlation with hemoglobin A1c, triglycerides, total cholesterol, LDL cholesterol, and apolipoprotein B in patients with type 1 diabetes.
PCSK9 had a significant correlation with hemoglobin A1c, triglycerides, total cholesterol, LDL cholesterol, and apolipoprotein B in patients with type 1 diabetes.
A decreased risk in Parkinson’s disease has been associated with total serum cholesterol and low-density lipoprotein cholesterol in men not on statin therapy.
In a study,patients with type 2 diabetes presented better glycemic control and had higher risk for mortality when not taking statins.
Two research groups successfully reduced cholesterol in humans to block the angiopoietin-like 3 gene.
Evacetrapib does not affect the primary efficacy end point of first occurrence of any component of a composite of death from cardiovascular causes in patients with high-risk vascular disease.
No differences were observed between pravastatin and usual care for CHD events, cause-specific deaths, stroke, cancer, and combination fatal CHD or nonfatal MI.
Study shows prevalence of atherosclerotic cardiovascular disease risk among adults under 50 without diabetes is low.
Social smokers have the same risk level for hypertension and elevated cholesterol as regular smokers.
Muscle-related adverse event reports increase when patients and doctors know that statins are being used.
Pitavastatin had greater low-density lipoprotein-lowering effects than pravastatin.